SI-BONE to Present at the 40th Annual Canaccord Genuity Growth Conference

Rhea-AI Summary

SI-BONE, a medical device company focused on sacropelvic disorders, announced its participation in the 40th Annual Canaccord Genuity Growth Conference. The company will conduct a live Fireside Chat on August 12, 2020, at 1:00 p.m. ET. Interested individuals can access the webcast via the company's website. SI-BONE's iFuse Implant System, designed for minimally invasive sacroiliac joint fusion, is supported by multiple clinical studies demonstrating its effectiveness in treating chronic low back pain. The device has been commercially available since 2009 and is covered by various insurance payors.

SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 40^th Annual Canaccord Genuity Growth Conference that is being held virtually.

SI-BONE’s management is scheduled for a live Fireside Chat on Wednesday, August 12, 2020 at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time. Interested parties may access a live and archived webcast of the event on the “Investors” section of the company’s website at: www.si-bone.com.

About SI-BONE

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.  Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain.  The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two RCTs, showing improved pain, patient function and quality of life resulting from treatment.  There are over 80 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results).  This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.  This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months.  The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. As well, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System.  It may not be appropriate for all patients and all patients may not benefit.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2020 SI-BONE, Inc. All Rights Reserved. 10804.07302020

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When is the SI-BONE Fireside Chat at the Canaccord Genuity Growth Conference?

The SI-BONE Fireside Chat is scheduled for August 12, 2020, at 1:00 p.m. Eastern Time.

How can I access the SI-BONE conference webcast?

You can access the live and archived webcast of the SI-BONE conference on the Investors section of their website.

What is the iFuse Implant System used for?

The iFuse Implant System is used for sacroiliac fusion to treat conditions such as sacroiliac joint dysfunction and to stabilize the sacroiliac joint.

What clinical evidence supports the iFuse Implant System?

The iFuse Implant System is supported by multiple clinical studies, including two randomized controlled trials (RCTs) demonstrating its safety and effectiveness.

Is the iFuse Implant System covered by insurance?

Yes, multiple government and private insurance payors cover the SI joint fusion procedure using the iFuse Implant System.